Corcept Therapeutics Incorporated (NASDAQ: CORT) will present new data from its Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA